Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis.

ABSTRACT:

Background

Sepsis remains a major clinical challenge characterized by dysregulated immune response, coagulation abnormalities, and multiorgan failure, leading to high morbidity and mortality.

Objectives

This study investigated the therapeutic potential of abelacimab, a monoclonal antibody targeting the plasma zymogen factor (F)XI, in a new baboon model of Staphylococcus aureus sepsis.

Methods

Healthy Papio anubis baboons were randomly assigned to control or abelacimab treatment groups. Both groups (n = 6, each) were intravenously infused with a median lethal (LD₅₀) dose of live S aureus. The treatment group was administered abelacimab 30 minutes after the onset of bacterial infusion. Hematologic, coagulation, inflammatory, and organ function parameters were

SUBMITTER: Silasi R 

PROVIDER: S-EPMC12668790 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature